Encompass Health CAO receives stock awards

Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price.

Rhea-AI Filing Summary

Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price. He acquired 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026, both at a stated price of $0.00 per share.

The 8,178-share issuance reflects restricted stock delivered after meeting performance criteria from a February 23, 2023 performance share unit award. The 1,560-share grant is an annual restricted stock award under the company’s 2025 Omnibus Performance Incentive Plan.

Insider Trade Summary

Grant/Award: 9,738 shares

Grant/Award 2 txns

Insider Price Andrew L

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	1,560	$0.00	$0.00
Grant/Award	Encompass Health Common Stock	8,178	$0.00	$0.00

Holdings After Transaction: Encompass Health Common Stock — 79,325 shares (Direct)

Footnotes (2)

1. F1. This issuance of restricted stock is the result of the satisfaction performance criteria set out in the terms of a performance share unit award made on February 23, 2023.
2. F2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Encompass Health (EHC) report for Andrew L. Price?

Encompass Health reported that Chief Accounting Officer Andrew L. Price received two restricted stock awards, totaling 9,738 shares of common stock, on February 18 and 19, 2026. These awards increased his directly held Encompass Health share balance as disclosed in the filing.

How many Encompass Health (EHC) shares were granted to the CAO on each date?

Andrew L. Price was granted 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026. Both transactions were reported as stock awards at a stated price of $0.00 per share in the Form 4.

What is the source of the 8,178-share Encompass Health (EHC) award?

The 8,178-share issuance represents restricted stock delivered after satisfying performance criteria from a performance share unit award granted on February 23, 2023. The Form 4 footnote explains that the award converted into restricted shares based on those performance conditions.

What plan governs the 1,560-share Encompass Health (EHC) stock award?

The 1,560-share restricted stock grant is described as an annual award under Encompass Health’s 2025 Omnibus Performance Incentive Plan. This plan provides equity-based compensation, and the award increased Andrew L. Price’s directly owned common stock holdings according to the filing.

Did Andrew L. Price buy or sell Encompass Health (EHC) stock on the open market?

The Form 4 shows grant or award acquisitions of restricted stock, not open-market purchases or sales. Both reported transactions use transaction code “A” for grant, award, or other acquisition, with a reported price of $0.00 per share for each award.

How many Encompass Health (EHC) shares does the CAO hold after these awards?

After the February 19, 2026 award, Andrew L. Price is reported to directly own 79,325 shares of Encompass Health common stock. The earlier transaction shows 77,765 shares following the 8,178-share issuance, and the later grant brought the total to the higher disclosed balance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 03:43 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Price Andrew L

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	02/18/2026		A		8,178(1)	A	$0	77,765	D
Encompass Health Common Stock	02/19/2026		A		1,560(2)	A	$0	79,325	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This issuance of restricted stock is the result of the satisfaction performance criteria set out in the terms of a performance share unit award made on February 23, 2023.

2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

	/s/ Patrick Darby, attorney-in-fact for Mr. Price	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.